Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab

Acta Neurol Belg. 2020 Feb;120(1):231-232. doi: 10.1007/s13760-019-01227-y. Epub 2019 Oct 25.

Authors

Simona Lattanzi¹, Giulia Carlini², Maria Cristina Acciarri², Maura Danni², Mauro Silvestrini²

Affiliations

¹ Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy. alfierelattanzisimona@gmail.com.
² Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy.

PMID: 31654393
DOI: 10.1007/s13760-019-01227-y

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Erythema Infectiosum / immunology*
Humans
Immunocompromised Host*
Immunologic Factors / adverse effects*
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
ocrelizumab